Tokyo, Japan

Shin Miyakawa

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 28(Granted Patents)


Company Filing History:


Years Active: 2011-2019

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Innovations of Shin Miyakawa

Introduction

Shin Miyakawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of aptamers. With a total of 7 patents to his name, his work has the potential to impact various medical applications.

Latest Patents

Miyakawa's latest patents include groundbreaking inventions such as an aptamer for nerve growth factor (NGF) and an aptamer against midkine. The first patent provides an aptamer that exhibits inhibitory activity against NGF, along with a complex that includes this aptamer and functional substances like drugs and diagnostic agents. The second patent focuses on an aptamer that binds to midkine, capable of forming a specific secondary structure, which is crucial for its functionality.

Career Highlights

Throughout his career, Shin Miyakawa has worked with notable companies, including Ribomic Inc. and NTT Communications Corporation. His experience in these organizations has allowed him to refine his skills and contribute to innovative projects in the biotechnology sector.

Collaborations

Miyakawa has collaborated with esteemed colleagues such as Yoshikazu Nakamura and Masatoshi Fujiwara. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Shin Miyakawa's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical applications, showcasing the importance of innovation in improving healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…